Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CORT Corcept Therapeutics

Market Closed 03-20 16:00:00 EDT

34.64

+0.56

+1.64%

盘后35.01

+0.37+1.07%

19:42 EDT

High36.35	Low34.46	Vol3.21M
Open35.50	D1 Closing34.08	Amplitude5.55%
Mkt Cap3.68B	Tradable Cap3.01B	Total Shares106.37M
T/O112.20M	T/O Rate3.69%	Tradable Shares86.88M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CORT","market":"US","secType":"STK","nameCN":"Corcept Therapeutics","latestPrice":34.64,"timestamp":1774036800000,"preClose":34.08,"halted":0,"volume":3205427,"hourTrading":{"tag":"盘后","latestPrice":35.01,"preClose":34.64,"latestTime":"19:42 EDT","volume":235055,"amount":8142564.767396,"timestamp":1774050142806,"change":0.37,"changeRate":0.010681,"amplitude":0.010681},"delay":0,"changeRate":0.016431924882629175,"floatShares":86875270,"shares":106374020,"eps":0.82,"marketStatus":"Market Closed","change":0.56,"latestTime":"03-20 16:00:00 EDT","open":35.5,"high":36.35,"low":34.46,"amount":112199641.416675,"amplitude":0.055458,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.82,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774252800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1081915200000,"exchange":"NASDAQ","adjPreClose":34.08,"preHourTrading":{"tag":"盘前","latestPrice":35.49,"preClose":34.08,"latestTime":"09:29 EDT","volume":11431,"amount":404936.20209000004,"timestamp":1774013399999,"change":1.41,"changeRate":0.041373,"amplitude":0.017606},"postHourTrading":{"tag":"盘后","latestPrice":35.01,"preClose":34.64,"latestTime":"19:42 EDT","volume":235055,"amount":8142564.767396,"timestamp":1774050142806,"change":0.37,"changeRate":0.010681,"amplitude":0.010681},"volumeRatio":2.809885353758631,"impliedVol":0.4817,"impliedVolPercentile":0.1952},"requestUrl":"/m/hq/s/CORT/tweets","defaultTab":"tweets","newsList":[{"id":"2620271975","title":"Corcept Therapeutics Director G. Leonard Baker Jr acquires USD 3.31 million in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620271975","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620271975?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:08","pubTimestamp":1773954497,"startTime":"0","endTime":"0","summary":"Corcept director Leonard Baker Jr reported open-market purchases totaling 100,000 common shares.The purchases were reported at USD 33 per share and USD 33.56 per share.Following the transactions, Baker held 1,146,631 common shares directly.The filing also reported 3,308,303 common shares held indirectly through a limited partnership.An additional 1,095,262 common shares were reported as held indirectly through a trust.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 19, 2026, and is solely responsible f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL7Qm8rJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Corcept Therapeutics Director G. Leonard Baker Jr acquires USD 3.31 million in common shares","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","BK4532","CORT","BK4007","LU0566484027.USD"],"gpt_icon":0},{"id":"2620986352","title":"Corcept faces class action over relacorilant NDA claims after 50.4% stock drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2620986352","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620986352?lang=en_us&edition=fundamental","pubTime":"2026-03-19 05:35","pubTimestamp":1773869727,"startTime":"0","endTime":"0","summary":"A class action lawsuit was filed on behalf of investors who purchased Corcept common stock between Oct. 31, 2024, and Dec. 30, 2025. The complaint alleges Corcept misled investors about the clinical evidence supporting its relacorilant new drug application for hypercortisolism and the risk of non-approval. Corcept disclosed it received an FDA Complete Response Letter stating the agency could not reach a favorable benefit-risk assessment without additional evidence of effectiveness. Corcept shares fell 50.4% from $70.2 to $34.8 following the disclosure.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL6cVJdv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU0566484027.USD","BK4007","CORT","LU1559883803.SGD"],"gpt_icon":0},{"id":"2620472358","title":"Class action lawsuit targets Corcept Therapeutics over alleged securities law violations","url":"https://stock-news.laohu8.com/highlight/detail?id=2620472358","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620472358?lang=en_us&edition=fundamental","pubTime":"2026-03-18 02:00","pubTimestamp":1773770417,"startTime":"0","endTime":"0","summary":"A securities class action lawsuit has been filed against Corcept and certain officers, alleging violations of federal securities laws. The suit seeks damages on behalf of investors who bought or acquired Corcept securities between Oct. 31, 2024 and Dec. 30, 2025. The complaint alleges Corcept overstated the strength of clinical trial support for relacorilant in connection with its FDA new drug application. It also alleges the company gave an inaccurate impression of regulatory prospects despite repeated FDA concerns about the adequacy of the clinical evidence.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL6Tj2VY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","IE00BGHQF748.EUR","LU0314104364.USD","SG9999014039.USD","IE00B64PRP62.GBP","NDAQ","BK4112","BK4532","SG9999014005.SGD","BK4007","SG9999014013.SGD","IE00BKPKM429.USD","LU2210149790.SGD","BK4585","IE00B3QW5Z07.USD","CORT","IE00BN0W2T93.GBP","LU0566484027.USD","BK4588","IE00BN0W2W23.USD","LU2095319765.USD","SG9999014021.USD","IE00BN0W2V16.EUR","LU2210150020.SGD"],"gpt_icon":0},{"id":"2619468437","title":"Wolf Haldenstein files securities class action against Corcept Therapeutics over relacorilant statements","url":"https://stock-news.laohu8.com/highlight/detail?id=2619468437","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619468437?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:21","pubTimestamp":1773663677,"startTime":"0","endTime":"0","summary":"A securities class action lawsuit was filed against Corcept on behalf of investors who purchased the company’s securities between Oct. 31, 2024 and Dec. 30, 2025. The complaint alleges the company made materially false or misleading statements about the clinical trial evidence supporting relacorilant and its New Drug Application to the FDA. It also alleges Corcept expressed confidence about regulatory approval despite the FDA raising concerns about the adequacy of the clinical evidence. Investors have until April 21, 2026 to seek appointment as lead plaintiff.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL7Qx41l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4007","LU2095319765.USD","IE00BN0W2T93.GBP","LU1559883803.SGD","SG9999014021.USD","IE00BN0W2W23.USD","LU2210150020.SGD","IE00BGHQF748.EUR","BK4532","BK4585","SG9999014005.SGD","IE00BKPKM429.USD","BK4112","NDAQ","SG9999014039.USD","CORT","LU0566484027.USD","SG9999014013.SGD","BK4588","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","LU0314104364.USD"],"gpt_icon":0},{"id":"2619104129","title":"Corcept Therapeutics (CORT) Is Down 5.1% After FDA Relacorilant Rejection And Investor Lawsuits - What's Changed","url":"https://stock-news.laohu8.com/highlight/detail?id=2619104129","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619104129?lang=en_us&edition=fundamental","pubTime":"2026-03-15 21:22","pubTimestamp":1773580933,"startTime":"0","endTime":"0","summary":"In late 2025, Corcept Therapeutics received a Complete Response Letter from the FDA rejecting its New Drug Application for relacorilant on the grounds of insufficient evidence of effectiveness, prompting multiple securities class action lawsuits alleging the company misrepresented the drug’s regulatory prospects and prior FDA feedback.\nThese lawsuits focus not just on the setback for relacorilant, but on claims that Corcept withheld repeated FDA concerns while continuing to promote the drug...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/corcept-therapeutics-cort-is-down-51-after-fda-relacorilant","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/corcept-therapeutics-cort-is-down-51-after-fda-relacorilant","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","CORT","LU1559883803.SGD","LU0566484027.USD","LABU","BK4532","BK4585","BK4588"],"gpt_icon":0},{"id":"2617581826","title":"Corcept Chief Development Officer William Guyer Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2617581826","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617581826?lang=en_us&edition=fundamental","pubTime":"2026-03-07 05:31","pubTimestamp":1772832687,"startTime":"0","endTime":"0","summary":"William Guyer, Chief Development Officer of Corcept Therapeutics Incorporated, reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL6tWHXq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Corcept Chief Development Officer William Guyer Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","LU0566484027.USD","BK4007","BK4532","CORT"],"gpt_icon":0},{"id":"2617752473","title":"Corcept Investors Face April 21 Lead Plaintiff Deadline in Securities Fraud Class Action","url":"https://stock-news.laohu8.com/highlight/detail?id=2617752473","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617752473?lang=en_us&edition=fundamental","pubTime":"2026-03-06 01:00","pubTimestamp":1772730051,"startTime":"0","endTime":"0","summary":"Glancy Prongay Wolke and Rotter has reminded investors of an April 21, 2026 deadline to seek lead-plaintiff status in a proposed securities fraud class action involving Corcept Therapeutics. The suit covers shareholders who bought Corcept stock between Oct. 31, 2024 and Dec. 30, 2025, and alleges the company misled investors about FDA concerns over the clinical program supporting its relacorilant application. Corcept shares fell about 50 percent on Dec. 31, 2025 after the FDA issued a complete response letter declining to approve the drug.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDLCNmv3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","SG9999014021.USD","LU2095319765.USD","LU1559883803.SGD","SG9999014039.USD","BK4585","BK4588","LU2210150020.SGD","IE00BKPKM429.USD","LU2210149790.SGD","LU0314104364.USD","SG9999014005.SGD","NDAQ","CORT","BK4532","IE00B3QW5Z07.USD","SG9999014013.SGD","BK4007","LU0566484027.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2617568286","title":"Hagens Berman Files Securities Class Action Against Corcept Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2617568286","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617568286?lang=en_us&edition=fundamental","pubTime":"2026-03-05 02:28","pubTimestamp":1772648917,"startTime":"0","endTime":"0","summary":"A securities class action lawsuit has been filed against Corcept Therapeutics Incorporated and certain executives in the U.S. District Court for the Northern District of California. The suit seeks to recover investor losses tied to purchases of Corcept common stock between October 31, 2024, and December 30, 2025, alleging the company misled the market about the regulatory prospects for its drug candidate relacorilant despite reported FDA warnings that the clinical data was inadequate. The complaint points to a sharp share-price drop after Corcept disclosed on December 31, 2025 that it received a Complete Response Letter from the FDA, and notes an April 21, 2026 deadline to seek lead plaintiff status.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL9r03zk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU2095319765.USD","IE00BKPKM429.USD","BK4585","SG9999014039.USD","IE00BGHQF748.EUR","CORT","SG9999014005.SGD","BK4532","IE00B3QW5Z07.USD","SG9999014021.USD","NDAQ","LU0566484027.USD","LU0314104364.USD","BK4588","LU2210150020.SGD","LU2210149790.SGD","SG9999014013.SGD","IE00B64PRP62.GBP","BK4112","LU1559883803.SGD"],"gpt_icon":0},{"id":"2616616559","title":"Canaccord Genuity Sticks to Its Buy Rating for Corcept Therapeutics (CORT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616616559","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616616559?lang=en_us&edition=fundamental","pubTime":"2026-03-04 22:36","pubTimestamp":1772634962,"startTime":"0","endTime":"0","summary":"In a report released today, Edward Nash from Canaccord Genuity maintained a Buy rating on Corcept Therapeutics, with a price target of $100.00. Nas...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-sticks-to-its-buy-rating-for-corcept-therapeutics-cort-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-sticks-to-its-buy-rating-for-corcept-therapeutics-cort-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CORT"],"gpt_icon":0},{"id":"2616375545","title":"Pomerantz Files Class Action Lawsuit Against Corcept Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2616375545","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616375545?lang=en_us&edition=fundamental","pubTime":"2026-03-04 03:02","pubTimestamp":1772564578,"startTime":"0","endTime":"0","summary":"A securities class action lawsuit has been filed against Corcept Therapeutics Incorporated, alleging the company and certain executives and directors engaged in securities fraud and other unlawful business practices. The litigation follows the company’s disclosure that the FDA issued a Complete Response Letter for relacorilant’s New Drug Application in hypertension secondary to hypercortisolism, saying additional evidence of effectiveness was needed; Corcept shares fell 50.4% on December 31, 2025. Investors who purchased Corcept securities during the class period have until April 21, 2026, to seek appointment as lead plaintiff.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL34MSLq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","IE00B3QW5Z07.USD","BK4585","IE00B64PRP62.GBP","CORT","NDAQ","LU1559883803.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4588","BK4112","SG9999014039.USD","BK4007","LU2095319765.USD","SG9999014005.SGD","BK4532","LU0566484027.USD","SG9999014013.SGD","LU2210149790.SGD","LU0314104364.USD","LU2210150020.SGD"],"gpt_icon":0},{"id":"1154789268","title":"Stock Track | Corcept Therapeutics Plummets 5.06% Intraday Following Securities Fraud Class Action Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=1154789268","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154789268?lang=en_us&edition=fundamental","pubTime":"2026-03-04 00:04","pubTimestamp":1772553886,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics' stock plummeted 5.06% during intraday trading on Tuesday, following news of legal action against the company. The sharp decline comes after the Schall Law Firm filed a...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CORT"],"gpt_icon":0},{"id":"2616739365","title":"Rosen Law Firm Files Securities Class Action Against Corcept Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2616739365","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616739365?lang=en_us&edition=fundamental","pubTime":"2026-03-03 04:42","pubTimestamp":1772484156,"startTime":"0","endTime":"0","summary":"Rosen Law Firm is encouraging investors who bought Corcept Therapeutics common stock between Oct. 31, 2024 and Dec. 30, 2025 to seek legal counsel ahead of an April 21, 2026 deadline to move for lead plaintiff status in a securities class action. The lawsuit alleges the company misled investors about the strength of clinical trial evidence and FDA communications supporting its relacorilant new drug application for hypercortisolism, and that undisclosed FDA concerns created a material risk the application would not be approved, causing investor losses when the information emerged.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL8GL81Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","SG9999014021.USD","LU2095319765.USD","LU1559883803.SGD","SG9999014039.USD","BK4585","BK4588","LU2210150020.SGD","IE00BKPKM429.USD","LU2210149790.SGD","LU0314104364.USD","SG9999014005.SGD","NDAQ","CORT","BK4532","IE00B3QW5Z07.USD","SG9999014013.SGD","BK4007","LU0566484027.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2614898508","title":"Rosen Law Firm Urges Corcept Investors to Seek Counsel Before April 21 Lead Plaintiff Deadline","url":"https://stock-news.laohu8.com/highlight/detail?id=2614898508","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614898508?lang=en_us&edition=fundamental","pubTime":"2026-02-28 06:30","pubTimestamp":1772231423,"startTime":"0","endTime":"0","summary":"A securities class action lawsuit has been filed on behalf of investors who bought Corcept Therapeutics common stock between Oct. 31, 2024 and Dec. 30, 2025. The complaint alleges the company misled investors about the strength of clinical evidence and regulatory prospects for its relacorilant new drug application, and says investors were harmed when concerns about FDA approval risk emerged. Investors seeking to be appointed lead plaintiff must file a motion by April 21, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDL3yGSQr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","SG9999014021.USD","LU2095319765.USD","LU1559883803.SGD","SG9999014039.USD","BK4585","BK4588","LU2210150020.SGD","IE00BKPKM429.USD","LU2210149790.SGD","LU0314104364.USD","SG9999014005.SGD","NDAQ","CORT","BK4532","IE00B3QW5Z07.USD","SG9999014013.SGD","BK4007","LU0566484027.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2614928007","title":"Portnoy Law Firm Files Class Action Against Corcept Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2614928007","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614928007?lang=en_us&edition=fundamental","pubTime":"2026-02-27 11:40","pubTimestamp":1772163623,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed on behalf of investors in Corcept Therapeutics Incorporated who purchased securities between Oct. 31, 2024 and Dec. 31, 2025. The complaint alleges the company misled investors about the strength of clinical evidence and the likelihood of FDA approval for its relacorilant new drug application, before disclosing it had received an FDA Complete Response Letter seeking additional evidence of effectiveness, after which Corcept shares fell more than 50%. Investors have until April 21, 2026 to seek appointment as lead plaintiff.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDL2XtvFD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","IE00BGHQF748.EUR","BK4532","BK4112","SG9999014005.SGD","BK4588","SG9999014013.SGD","NDAQ","LU2210149790.SGD","IE00B64PRP62.GBP","BK4007","CORT","LU2210150020.SGD","IE00B3QW5Z07.USD","LU0314104364.USD","LU0566484027.USD","SG9999014039.USD","LU1559883803.SGD","IE00BKPKM429.USD","BK4585","LU2095319765.USD"],"gpt_icon":0},{"id":"2614047011","title":"Robbins LLP Alerts Corcept Investors to Lead Plaintiff Deadline in Class Action Lawsuit","url":"https://stock-news.laohu8.com/highlight/detail?id=2614047011","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614047011?lang=en_us&edition=fundamental","pubTime":"2026-02-26 22:00","pubTimestamp":1772114443,"startTime":"0","endTime":"0","summary":"A securities class action lawsuit has been filed against Corcept Therapeutics Incorporated on behalf of investors who bought the company’s common stock between October 31, 2024 and December 30, 2025. The suit alleges the company misled investors about the strength of clinical evidence and the likelihood of FDA approval for its drug candidate relacorilant for hypercortisolism, before the FDA issued a Complete Response Letter on December 31, 2025 seeking additional evidence of effectiveness, triggering a sharp stock decline.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL5Gj3S5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT","BK4532","IE00BGHQF748.EUR","SG9999014005.SGD","BK4588","LU0314104364.USD","IE00B3QW5Z07.USD","BK4007","NDAQ","SG9999014039.USD","BK4112","LU2095319765.USD","LU2210149790.SGD","LU2210150020.SGD","BK4585","SG9999014013.SGD","LU0566484027.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU1559883803.SGD","SG9999014021.USD"],"gpt_icon":0},{"id":"2614067882","title":"Lead Plaintiff Deadline Set in Corcept Therapeutics Securities Class Action","url":"https://stock-news.laohu8.com/highlight/detail?id=2614067882","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614067882?lang=en_us&edition=fundamental","pubTime":"2026-02-26 11:14","pubTimestamp":1772075681,"startTime":"0","endTime":"0","summary":"A securities class action lawsuit has been filed against Corcept Therapeutics Incorporated in the U.S. District Court for the Northern District of California. The case covers investors who bought or acquired Corcept shares between Oct. 31, 2024 and Dec. 30, 2025, and investors seeking to serve as lead plaintiff must file an application by April 21, 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL2QmN44:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","LU2210150020.SGD","BK4007","BK4532","NDAQ","SG9999014021.USD","LU2095319765.USD","SG9999014039.USD","BK4112","CORT","LU0566484027.USD","SG9999014005.SGD","BK4588","LU0314104364.USD","SG9999014013.SGD","BK4585","LU1559883803.SGD"],"gpt_icon":0},{"id":"1156227825","title":"Stock Track | Corcept Therapeutics Plummets 5.15% Intraday Following Analyst Price Target Cuts","url":"https://stock-news.laohu8.com/highlight/detail?id=1156227825","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156227825?lang=en_us&edition=fundamental","pubTime":"2026-02-26 01:22","pubTimestamp":1772040142,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics (CORT) stock plummeted 5.15% during intraday trading on Wednesday, as the market reacted to negative analyst sentiment.The decline follows reports that at least two major...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CORT"],"gpt_icon":0},{"id":"2614084562","title":"Corcept Therapeutics Inc : Piper Sandler Cuts Target Price to $73 From $121","url":"https://stock-news.laohu8.com/highlight/detail?id=2614084562","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614084562?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:31","pubTimestamp":1772022714,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZL1H8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4532","LU0566484027.USD","BK4007","LU1559883803.SGD","CORT"],"gpt_icon":0},{"id":"2614308900","title":"Corcept Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2614308900","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614308900?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:03","pubTimestamp":1772020980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CORT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 25, 2026 07:03 ET (12:03 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT"],"gpt_icon":0},{"id":"2614085482","title":"Corcept Therapeutics price target lowered to $60 from $67 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2614085482","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614085482?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:13","pubTimestamp":1772018005,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm’s price target on Corcept Therapeutics (CORT) to $60 from $67 and keeps a Buy ratin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-price-target-lowered-to-60-from-67-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-price-target-lowered-to-60-from-67-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CORT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.corcept.com","stockEarnings":[{"period":"1week","weight":0.0774},{"period":"1month","weight":-0.1301},{"period":"3month","weight":-0.5864},{"period":"6month","weight":-0.5698},{"period":"1year","weight":-0.3985},{"period":"ytd","weight":-0.0046}],"compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":-0.055},{"period":"3month","weight":-0.047},{"period":"6month","weight":-0.0228},{"period":"1year","weight":0.1469},{"period":"ytd","weight":-0.0489}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.022337},{"month":2,"riseRate":0.409091,"avgChangeRate":0.008661},{"month":3,"riseRate":0.727273,"avgChangeRate":0.133515},{"month":4,"riseRate":0.52381,"avgChangeRate":-0.001402},{"month":5,"riseRate":0.5,"avgChangeRate":0.00703},{"month":6,"riseRate":0.454545,"avgChangeRate":0.039099},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.006529},{"month":8,"riseRate":0.409091,"avgChangeRate":-0.006283},{"month":9,"riseRate":0.454545,"avgChangeRate":0.062175},{"month":10,"riseRate":0.5,"avgChangeRate":-0.005789},{"month":11,"riseRate":0.5,"avgChangeRate":0.018834},{"month":12,"riseRate":0.409091,"avgChangeRate":0.027449}],"exchange":"NASDAQ","name":"Corcept Therapeutics","nameEN":"Corcept Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Corcept Therapeutics(CORT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Corcept Therapeutics,CORT,Corcept Therapeutics股票,Corcept Therapeutics股票老虎,Corcept Therapeutics股票老虎国际,Corcept Therapeutics行情,Corcept Therapeutics股票行情,Corcept Therapeutics股价,Corcept Therapeutics股市,Corcept Therapeutics股票价格,Corcept Therapeutics股票交易,Corcept Therapeutics股票购买,Corcept Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Corcept Therapeutics(CORT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}